Medical devices and digital technologies

TympanoColl: a new technology for the fast and effective repair of damaged tympanic membranes

Repairing damage to the eardrum (Tympanic Membrane) traditionally uses an invasive surgical procedure using the patient’s own donor tissue. The procedure also requires general anaesthetic, a large incision at the back of the ear, and cannot be completed in an outpatient setting. TympanoColl, is a patented combination of (i) a new biodegradable implant with (ii) an innovative single-step delivery system to repair the ear drum via the ear canal quickly, easily and safely in an outpatient setting

This technology is being commercialised by RCSI spin-out company Tympulse Medical.

PReduction: an implantable cardiac pump to treat heart failure with preserved ejection fraction (HFpEF)

HFpEF currently accounts for approximately 50% of all the cases of HF and is estimated to cost the US healthcare system $26.55 billion by 2030. To date, no pharmacological or device-based therapy has yet been shown to improve survival in randomised controlled trials of patients with HFpEF. PumpinHeart is developing PReduction, a transcatheter implantable left ventricular assist device (LVAD) for the treatment of HFpEF.

This technology is being commercialised by RCSI spin-out company Pumpinheart.

Objective medication adherence calculator – a tool to aid patient adherence and optimise drug dosage

Assessing adherence to medication is an essential element in the ongoing treatment of patients with chronic disease as well as in the development and trialling of new drugs. RCSI has developed a novel data-driven decision support tool for clinicians to improve patient adherence and personalise medication dosage in chronic conditions such as COPD and asthma.

This technology is being commercialised by RCSI spin-out company Phyxiom.